Guanosine 3 ',5 '-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: Protective effects of propentofylline
F. Wirtz-brugger et A. Giovanni, Guanosine 3 ',5 '-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: Protective effects of propentofylline, NEUROSCIENC, 99(4), 2000, pp. 737-750
Apoptotic cell death has been implicated in Alzheimer's disease pathology a
nd amyloid peptide induced neurotoxicity. We investigated the survival prom
oting effects of Propentofylline in two models of apoptotic cell death, ner
ve growth factor withdrawal and beta-amyloid mediated cell death in nerve g
rowth factor differentiated rat pheochromocytoma cell lines. The increase i
n cell death as measured by lactate dehydrogenase release in response to ne
rve growth factor withdrawal was suppressed by nitric oxide donor S-nitroso
-N-acetylpenicillamine (12.5 to 200 mu M) and by 8-bromoguanosine-3',5'-cyc
lic monophosphate (1.25 to 10 mM). Both agents decreased cell death mediate
d by 25 mu M beta-amyloid, suggesting that the protective mechanism involve
s guanosine -3',5'-cyclic monophosphate. In support of this hypothesis we c
an show that S-nitroso-N-acetylpenicillamine increases intracellular levels
of guanosine -3',5'-cyclic monophosphate in pheochromocytoma cell lines 3
to 8 fold.
Propentofylline, a phosphodiesterase inhibitor, has previously demonstrated
neuroprotective activity in stroke models and is a potential candidate for
therapeutic treatment in neurodegenerative diseases. The present findings
support this claim by providing evidence that Propentofylline has protectiv
e effects in both nerve growth factor withdrawal and beta-amyloid mediated
cell death. Lactate dehydrogenase release was significantly reduced and cas
pase-3-like activity was attenuated after cotreatment with Propentofylline.
Furthermore Propentofylline dose responsively increases intracellular guan
osine 3',5'-cyclic monophosphate levels over the same dose range that provi
ded protection. We hypothesized that guanosine-3',5'-cyclic monophosphate i
s a key mediator of neuroprotection under these conditions. (C) 2000 IBRO.
Published by Elsevier Science Ltd. All rights reserved.